Drive innovation faster
Increase revenue opportunities and build better, differentiated products with remote patient monitoring and real-world evidence gathered across the care continuum.
Huma’s EU MDR Class IIb platform helps MedTech deliver on the promise of innovation through added value services, RWE collection and improved research support. Build stronger relationships with patients and customers while collecting insights to support the next phase of product development.
Increase patient and clinician engagement
Huma’s award-winning, patient-centric design improves clinician and patient engagement and outcomes, helping MedTech build stronger, longer-term relationships with care providers and customers. We have the potential to help clinicians by providing advice and recommendations for individual patients throughout their care journey.
We have a 90–95% adherence and retention rate1 across our care and research deployments as a result of our high engagement rates.
.png)
Increase patient and clinician engagement
We have a 90–95% adherence and retention rate1 across our care and research deployments as a result of our high engagement rates.
Explore novel reimbursement opportunities
The Huma platform can collect and provide actionable insights for a wider patient population due to its Class IIb certification.
Regulatory, safety and compliance
MHRA registered Medical Device Class IIb
Part 11
Part 50
Part 820 ff
ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
ISO 27001: 2013 certified
Committed to GDPR compliance
NHS Registration on Data Security and Protection Toolkit
CyberEssentials / CyberEssentials Plus
Optimise surgical waitlist management
Huma’s platform optimises surgical waitlists via pre- and post-surgical monitoring with proactive identification of patient deterioration. Smart alerts and individual patient thresholding and targeting ensure personalised care while maximising population health management.
Huma’s “Learn” module helps patients build understanding, confidence, and reassurance about their condition and ongoing plan of care, and is proven to support higher medication adherence.2
Request a meeting
Sources
Range of data from across a number of Huma projects
Sarraju, A., Seninger, C., Parameswaran, V. et al. Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP). npj Digit. Med. 5, 80 (2022). https://doi.org/10.1038/s41746-022-00622-9
https://www.nature.com/articles/s41746-022-00622-9
